Abstract Body

Background: Non-perinatally HIV (nPHIV)-infected youth are more likely to have delayed initiation of combination antiretroviral therapy (cART) and have higher nonadherence to cART than adults. Youth have residual thymic tissue and potentially greater capacity for immune reconstitution than adults. We compared CD4 responses to cART between nPHIV-infected youth (12-24 years-old) and adults (≥25-44 years-old). Methodology: Retrospective analysis of nPHIV-infected cART-naive individuals 12-44 years-old, who initiated their first cART between 2008 and 2011 at clinical sites in the HIV Research Network. Age was limited to <45 years to avoid the impact of co-morbidities with increasing age. A generalized linear mixed model assessed the association between the repeated outcomes of CD4 gain≥100 cells/mm3 at each visit after cART initiation and age category (12-24, 25-34, 35-44 years). The model accounted for random variation within each participant and between sites, and adjusted for gender, race/ethnicity, HIV acquisition risk, baseline CD4 and log10HIV-1 RNA, virologic suppression (<2.6 log), and cART duration. Results: Of 3,326 individuals (523 youth, 2803 adults) included, a greater proportion of youth vs. adults were male (83% vs. 74%, p<0.001), had MSM HIV acquisition (72% vs. 50%, p<0.001), and baseline CD4 200-349 cells/mm3 (40% vs. 31%, p<0.001). At 24 weeks after cART initiation, 45% vs. 39% (p=0.04) of youth vs. adults attained CD4 gain≥100 cells/mm3; subsequently, the proportion fell below that of adults. Virologic suppression rates for youth vs. adults were 74% vs. 73% (24-weeks) and 73% vs. 77% (48-weeks), p=0.3 (both). When adjusting for gender and race/ethnicity alone the adjusted odds ratio (AOR) of CD4 gain>=100 cells/mm3 was (1.2 (95% CI 0.93-1.6) and 1.3 (95% CI 1.0-1.6) for those 12-24 and 25-34 vs. 35-44 years; however, this effect was non-significant after adjusting for other potential confounders (See table). Conclusions: With virologic suppression, youth achieved CD4 gains ≥100 cells/mm3 earlier than adults, however, this trajectory was not sustained. CART initiation for youth should not be delayed with the expectation that residual capacity for immune reconstitution will result in greater CD4 responses. Maintaining virologic suppression is the most critical factor to enhancing CD4 outcomes, especially for youth who traditionally have higher nonadherence rates.